Evidence map›Paper›PMID 40232370›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2025

Optical coherence tomography reveals retinal structural abnormalities in α-synucleinopathies: insights from the Padua-CESNE cohort.

M Campagnolo, M Puthenparampil, A Emmi, L Weis, E Basili, V Mauceri, A Miscioscia, M Carecchio, A Guerra, V Misenti and 3 more

Abstract read
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M CampagnoloParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy. marta.campagnolo@unipd.it.ORCID 0000-0002-6394-7168
M Puthenparampil *Multiple Sclerosis Centre, Department of Neuroscience, University of Padova, Padua, Italy.
A Emmi *Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy.
L WeisIRCCS San Camillo Hospital, Venice, Italy.
E BasiliMultiple Sclerosis Centre, Department of Neuroscience, University of Padova, Padua, Italy.
V MauceriMultiple Sclerosis Centre, Department of Neuroscience, University of Padova, Padua, Italy.
A MisciosciaMultiple Sclerosis Centre, Department of Neuroscience, University of Padova, Padua, Italy.
M CarecchioParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy.
A GuerraParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy.
V MisentiParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy.
C FoglianoParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy.
P GalloMultiple Sclerosis Centre, Department of Neuroscience, University of Padova, Padua, Italy.
A AntoniniParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Via Giustiniani 3, 35121, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complexity of α-synucleinopathies, namely Parkinson's disease (PD) and multiple system atrophy (MSA), calls for the adoption a multimodal approach integrating biological, morphological, and functional data. Phosphorylated α-synuclein (α-syn) detection in bodily fluids and tissues such as the skin helps provide biological characterization of the disease, but specific and accessible biomarkers are not available yet. The aim of this study was to define the role of Optical Coherence Tomography (OCT, a minimally invasive retinal imaging technique) patterns as possible biomarkers in the early stages of α-synucleinopathies, also supporting the differential diagnosis. Thirty-five (23 PD, 12 MSA), clinically, biologically and genetically characterized patients included in the PADUA-CESNE (Centro Studi per la Neurodegenerazione) cohort underwent OCT. A significant atrophy in the inferior, superior and temporal regions of the Retinal Nerve Fiber Layer (RNFL) and in the inner nuclear layer (INL) were observed in PD compared to controls, differently from MSA. Hyperreflective foci (HRF) counts were elevated across all retinal layers in all patients with PD exhibiting significantly higher numbers, suggesting microglial activation and greater retinal damage. Further research regarding OCT patterns in PD and MSA may consolidate the role of specific features, such as INL abnormalities and different HRF counts, in supporting the diagnosis and differential diagnosis in α-synucleinopathies. In light of the availability of potentially disease-modifying therapies, studies should focus on newly diagnosed patients, also undergoing thorough clinical, biological and genetic characterization.

Indexed as

Multiple System AtrophyParkinson DiseaseRetinaSynucleinopathiesTomography, Optical CoherenceAgedalpha-SynucleinCohort StudiesFemaleHumansMaleMiddle Agedalpha-SynucleinBiomarkersMultiple system atrophyOptical coherence tomographyParkinson’s diseaseα-synuclein

Identifiers

PMID40232370
PMCPMC12208970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.